While the topics of lab testing and THC inflation have taken a relative rear seat in Massachusetts cannabis over the past year, they are back squarely in the spotlight. For that you can probably thank the chorus of scientists, from Independent Testing Labs (ITLs) and elsewhere, as well as the current Cannabis Control Commission leadership for ushering the issues forward.
But while the literal nature of lab testing is up for debate via new proposed testing regulations (you can read about that process here), there is also the question of eventual oversight. That is to say, How should the CCC monitor ITLs and their results?
As ridiculous as it may sound, up until now, there’s barely been an answer. The commission spent years basically dodging questions about an imagined secret shopper program, only to determine that it isn’t in the budget. There’s also been talk of the state building its own lab, which really isn’t in the budget, and which not everybody thinks is such a silver bullet anyway.
Those limitations notwithstanding, the current CCC members see the importance in this additional layer of oversight. After all, what’s the point of fixing testing if nobody’s gonna test the testers? I can’t speak for them, but as far as I know, the ITLs basically agree.
Speaking at last Thursday’s meeting about “how we would provide oversight for labs, particularly through the relationship with another lab,” Commissioner Anthony Wilson called this sheath “the backbone … whether we create it or whether we contract [with] another lab.” He outlined “three progressively more intense oversight functions that this lab might provide to us,” noting “these are not necessarily mutually exclusive or sequential.” Wilson offered three frameworks as follows:
- Retail Shelf Audit. In this version, “staff would obtain product from the market and using our own lab would have that uh product tested for contaminants as well as potency.” Wilson explained: “It is the most practical starting port point because it builds from existing shelf audit activity. A shelf failure can indicate a consumer safety concern, but it does not necessarily implicate an independent testing lab in any specific issue or error.”
- Interlaboratory Comparison Round Robin Testing. “Tier two would use … several laboratory tests, portions of comparably prepared products to create insight into consistency of reported results. It would complement rather than replace existing proficiency testing. [The state’s] laboratory would be one of the labs that receives this type of sample and they would be the anchor of truth as we went through this round robin process.”
- Standards Laboratory. “The third and really the second largest of these is a standards laboratory model in which up to 5% of cannabis product in the market is sent to our laboratory for testing at the same time that the testing sample is sent to the independent testing lab. This would be a robust way of measuring and determining that testing labs are doing what they have stated that they are going to do.”
Wilson said, “At a minimum, the commission seeks to establish the independent retail shelf audit testing program to enhance the identification of potentially unsafe product. Additional collaboration through inter-laboratory comparison studies and standards laboratory testing could further strengthen our laboratory oversight, improve the reliability of compliance testing, and support evidence-based regulatory decision-making.”
As has been the case when this subject has come up before, there is hardly any additional money in the CCC piggybank to proceed with any of these plans right now. Still, Wilson presented a timeline of “what the next 18 months could look like,” with a process that involves pilot-testing variant approaches and evaluating the results.
“Several independent factors affect whether and how the commission can engage a partner lab,” Wilson said. “We are considering multiple options across the state and facilities with existing labs and appreciate all potential partners we have had conversations with thus far. We have not entered into any agreement with any lab at this time and are evaluating all options.”